Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN102557977B details efficient Erlotinib intermediate synthesis offering cost reduction and supply chain reliability for API manufacturing partners.
Discover the advanced CN114853734A method for Nilotinib free base synthesis. Achieve higher purity and yield with optimized solvent systems for cost-effective manufacturing.
Patent CN102924548A details a safer Capecitabine synthesis using Lewis acids instead of toxic tin, offering cost reduction and scalable manufacturing for pharmaceutical intermediates.
Patent CN112724089B details a high-yield bromination process for 2-amino-3-bromo-6-chloropyrazine, offering significant cost reduction and scalable production for SHP2 inhibitor intermediates.
Patent CN1507441A discloses novel tricyclic hydroxamates with superior antitumor activity. Discover scalable synthesis routes for high-purity pharmaceutical intermediates.
Novel FeCl3-catalyzed reduction method for high-purity 2-aminopyrimidine compounds, eliminating toxic iron sludge and difficult impurities for scalable API manufacturing.
Novel mesylate salt formation improves purity and yield. Reduces dimer impurities. Ideal for scalable pharma manufacturing.
Patent CN107428695B details a scalable Suzuki coupling for 2-chloro-4-(1H-pyrazol-3-yl)benzonitrile, reducing palladium usage and simplifying workup.
Patent CN117025699A reveals a chemo-enzymatic route for Larotinib intermediates. Achieve high ee values and reduced costs with scalable pharmaceutical manufacturing solutions.
Novel synthesis of 5-trifluoromethylpyrimidine derivatives via Buchwald-Hartwig coupling. High purity intermediates for anti-cancer drug development with scalable processes.
Patent CN108864057A details dual-target inhibitors for oncology. We offer scalable synthesis and cost reduction in pharmaceutical intermediates manufacturing for global partners.
Patent CN108101857B details a high-yield route for 2-amino-3-bromo-6-chloropyrazine, offering cost reduction in API manufacturing and reliable supply chain solutions.
Patent CN102548987A details novel fluoro-substituted compounds for Bcr-Abl inhibition. Discover scalable synthesis routes and cost-effective manufacturing strategies for high-purity pharmaceutical intermediates.
Advanced synthetic routes for MCL1 inhibitors offering scalable production and cost efficiency for pharmaceutical supply chains and R&D teams.
Novel quinoline kinase inhibitor synthesis offers high yield and purity for pharmaceutical intermediates, ensuring cost reduction and supply chain reliability.
Patent CN102558098A reveals a cost-effective one-pot synthesis for EGFR inhibitor intermediates, offering significant supply chain advantages for API manufacturers.
Patent CN102558098A details a one-pot synthesis for EGFR inhibitor intermediates, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Novel one-pot method replaces Pd catalysis for EGFR inhibitor intermediates, offering cost-effective scale-up and high purity for pharma supply chains.
Patent CN113636973B reveals a green industrial method for Palbociclib intermediates, offering high purity, cost reduction, and scalable manufacturing for global supply chains.
Patent CN113637002B reveals a green photocatalytic route for Nilaparib intermediates, offering significant cost reduction in API manufacturing and enhanced supply chain reliability.